CL2017002701A1 - Composiciones y métodos para la vigilancia activa del cáncer de próstata. - Google Patents

Composiciones y métodos para la vigilancia activa del cáncer de próstata.

Info

Publication number
CL2017002701A1
CL2017002701A1 CL2017002701A CL2017002701A CL2017002701A1 CL 2017002701 A1 CL2017002701 A1 CL 2017002701A1 CL 2017002701 A CL2017002701 A CL 2017002701A CL 2017002701 A CL2017002701 A CL 2017002701A CL 2017002701 A1 CL2017002701 A1 CL 2017002701A1
Authority
CL
Chile
Prior art keywords
prostate cancer
methods
compositions
active surveillance
surveillance
Prior art date
Application number
CL2017002701A
Other languages
English (en)
Inventor
Andrew J Vickers
Hans Lilja
Yan Dong
Daniel Sjoberg
Peter T Scardino
Original Assignee
Opko Diagnostics Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Opko Diagnostics Llc filed Critical Opko Diagnostics Llc
Publication of CL2017002701A1 publication Critical patent/CL2017002701A1/es

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/575—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57555—Immunoassay; Biospecific binding assay; Materials therefor for cancer of the prostate
    • G—PHYSICS
    • G06—COMPUTING OR CALCULATING; COUNTING
    • G06N—COMPUTING ARRANGEMENTS BASED ON SPECIFIC COMPUTATIONAL MODELS
    • G06N7/00—Computing arrangements based on specific mathematical models
    • G06N7/01—Probabilistic graphical models, e.g. probabilistic networks
    • G—PHYSICS
    • G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16B—BIOINFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR GENETIC OR PROTEIN-RELATED DATA PROCESSING IN COMPUTATIONAL MOLECULAR BIOLOGY
    • G16B20/00—ICT specially adapted for functional genomics or proteomics, e.g. genotype-phenotype associations
    • G—PHYSICS
    • G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16B—BIOINFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR GENETIC OR PROTEIN-RELATED DATA PROCESSING IN COMPUTATIONAL MOLECULAR BIOLOGY
    • G16B25/00—ICT specially adapted for hybridisation; ICT specially adapted for gene or protein expression
    • G16B25/10—Gene or protein expression profiling; Expression-ratio estimation or normalisation
    • G—PHYSICS
    • G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16H—HEALTHCARE INFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR THE HANDLING OR PROCESSING OF MEDICAL OR HEALTHCARE DATA
    • G16H10/00—ICT specially adapted for the handling or processing of patient-related medical or healthcare data
    • G16H10/40—ICT specially adapted for the handling or processing of patient-related medical or healthcare data for data related to laboratory analysis, e.g. patient specimen analysis
    • G—PHYSICS
    • G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16H—HEALTHCARE INFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR THE HANDLING OR PROCESSING OF MEDICAL OR HEALTHCARE DATA
    • G16H50/00—ICT specially adapted for medical diagnosis, medical simulation or medical data mining; ICT specially adapted for detecting, monitoring or modelling epidemics or pandemics
    • G16H50/20—ICT specially adapted for medical diagnosis, medical simulation or medical data mining; ICT specially adapted for detecting, monitoring or modelling epidemics or pandemics for computer-aided diagnosis, e.g. based on medical expert systems
    • G—PHYSICS
    • G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16H—HEALTHCARE INFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR THE HANDLING OR PROCESSING OF MEDICAL OR HEALTHCARE DATA
    • G16H50/00—ICT specially adapted for medical diagnosis, medical simulation or medical data mining; ICT specially adapted for detecting, monitoring or modelling epidemics or pandemics
    • G16H50/30—ICT specially adapted for medical diagnosis, medical simulation or medical data mining; ICT specially adapted for detecting, monitoring or modelling epidemics or pandemics for calculating health indices; for individual health risk assessment
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/90—Enzymes; Proenzymes
    • G01N2333/914—Hydrolases (3)
    • G01N2333/948—Hydrolases (3) acting on peptide bonds (3.4)
    • G01N2333/95—Proteinases, i.e. endopeptidases (3.4.21-3.4.99)
    • G01N2333/964—Proteinases, i.e. endopeptidases (3.4.21-3.4.99) derived from animal tissue
    • G01N2333/96425—Proteinases, i.e. endopeptidases (3.4.21-3.4.99) derived from animal tissue from mammals
    • G01N2333/96427—Proteinases, i.e. endopeptidases (3.4.21-3.4.99) derived from animal tissue from mammals in general
    • G01N2333/9643—Proteinases, i.e. endopeptidases (3.4.21-3.4.99) derived from animal tissue from mammals in general with EC number
    • G01N2333/96433—Serine endopeptidases (3.4.21)
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/90—Enzymes; Proenzymes
    • G01N2333/914—Hydrolases (3)
    • G01N2333/948—Hydrolases (3) acting on peptide bonds (3.4)
    • G01N2333/95—Proteinases, i.e. endopeptidases (3.4.21-3.4.99)
    • G01N2333/964—Proteinases, i.e. endopeptidases (3.4.21-3.4.99) derived from animal tissue
    • G01N2333/96425—Proteinases, i.e. endopeptidases (3.4.21-3.4.99) derived from animal tissue from mammals
    • G01N2333/96427—Proteinases, i.e. endopeptidases (3.4.21-3.4.99) derived from animal tissue from mammals in general
    • G01N2333/9643—Proteinases, i.e. endopeptidases (3.4.21-3.4.99) derived from animal tissue from mammals in general with EC number
    • G01N2333/96433—Serine endopeptidases (3.4.21)
    • G01N2333/96441—Serine endopeptidases (3.4.21) with definite EC number
    • G01N2333/96455—Kallikrein (3.4.21.34; 3.4.21.35)

Landscapes

  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Physics & Mathematics (AREA)
  • Medical Informatics (AREA)
  • Biomedical Technology (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Immunology (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • Theoretical Computer Science (AREA)
  • Biotechnology (AREA)
  • Pathology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Genetics & Genomics (AREA)
  • General Physics & Mathematics (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Data Mining & Analysis (AREA)
  • Analytical Chemistry (AREA)
  • Primary Health Care (AREA)
  • Epidemiology (AREA)
  • Biophysics (AREA)
  • Spectroscopy & Molecular Physics (AREA)
  • Evolutionary Biology (AREA)
  • Bioinformatics & Computational Biology (AREA)
  • Databases & Information Systems (AREA)
  • Microbiology (AREA)
  • Food Science & Technology (AREA)
  • Cell Biology (AREA)
  • Biochemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Artificial Intelligence (AREA)
  • General Engineering & Computer Science (AREA)
  • Mathematical Analysis (AREA)
  • Computational Mathematics (AREA)
  • Mathematical Optimization (AREA)
  • Computing Systems (AREA)

Abstract

<p>ASPECTOS DE LA DIVULGACIÓN SE REFIEREN A MÉTODOS Y SISTEMAS MEJORADOS PARA LA VIGILANCIA ACTIVA DE UN SUJETO QUE TIENE CÁNCER DE PRÓSTATA NO AGRESIVO.</p>
CL2017002701A 2015-04-29 2017-10-25 Composiciones y métodos para la vigilancia activa del cáncer de próstata. CL2017002701A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201562154616P 2015-04-29 2015-04-29

Publications (1)

Publication Number Publication Date
CL2017002701A1 true CL2017002701A1 (es) 2018-07-06

Family

ID=57198800

Family Applications (1)

Application Number Title Priority Date Filing Date
CL2017002701A CL2017002701A1 (es) 2015-04-29 2017-10-25 Composiciones y métodos para la vigilancia activa del cáncer de próstata.

Country Status (20)

Country Link
US (2) US20160320394A1 (es)
EP (2) EP3247387A4 (es)
JP (1) JP6873916B2 (es)
KR (1) KR102527446B1 (es)
CN (1) CN107530412A (es)
AU (1) AU2016254127B2 (es)
CA (1) CA2982262A1 (es)
CL (1) CL2017002701A1 (es)
CO (1) CO2017010808A2 (es)
DE (1) DE202016008673U1 (es)
EA (1) EA039028B1 (es)
HK (2) HK1247824A1 (es)
IL (1) IL254833B (es)
MX (1) MX2017013881A (es)
MY (1) MY197117A (es)
PE (1) PE20180930A1 (es)
SG (1) SG11201708289TA (es)
TW (1) TWI766836B (es)
UA (1) UA125745C2 (es)
WO (1) WO2016176529A1 (es)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK2391451T3 (en) 2009-02-02 2018-10-15 Opko Diagnostics Llc STRUCTURES FOR MANAGING LIGHT INTERACTION WITH MICROFLUIDIC DEVICES
MY193914A (en) 2012-03-05 2022-11-01 Oy Arctic Partners Ab Methods and apparatuses for predicting risk of prostate cancer and prostate gland volume
US12326453B2 (en) 2014-03-28 2025-06-10 Opko Diagnostics, Llc Compositions and methods for active surveillance of prostate cancer
DK3123381T3 (da) 2014-03-28 2023-11-27 Opko Diagnostics Llc Sammensætninger og fremgangsmåder relateret til diagnose af prostatacancer
WO2016160545A1 (en) 2015-03-27 2016-10-06 Opko Diagnostics, Llc Prostate antigen standards and uses thereof
US10852310B2 (en) 2015-12-11 2020-12-01 Opko Diagnostics, Llc Fluidic systems involving incubation of samples and/or reagents
CA3006882C (en) 2015-12-29 2023-11-28 Opko Diagnostics, Llc Fluid collection device and related methods
US20210208146A1 (en) * 2018-05-16 2021-07-08 Opko Diagnostics, Llc Methods for detecting prostate cancer pathology associated with adverse outcomes

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7211397B2 (en) * 1999-04-30 2007-05-01 Beckman Coulter, Inc. Method of analyzing non-complexed forms of prostate specific antigen in a sample to improve prostate cancer detection
FI20002127A0 (fi) * 2000-09-27 2000-09-27 Artic Partners Oy Ab Uusi vasta-aine, immunomääritys ja menetelmä eturauhassyövän havaitsemiseksi
WO2011027310A1 (en) * 2009-09-03 2011-03-10 Koninklijke Philips Electronics N.V. Novel tumor markers
CA3016967C (en) 2010-04-16 2021-08-31 Opko Diagnostics, Llc Systems and devices for analysis of samples
MY193914A (en) * 2012-03-05 2022-11-01 Oy Arctic Partners Ab Methods and apparatuses for predicting risk of prostate cancer and prostate gland volume
JP2015524052A (ja) * 2012-05-16 2015-08-20 ファディア・アクチボラゲットＰｈａｄｉａ ＡＢ 前立腺癌の存在または不存在の提示方法
KR20150110477A (ko) * 2012-11-20 2015-10-02 파디아 에이비 공격적인 전립선 암의 존재 또는 부존재를 나타내는 방법
ES2694409T3 (es) * 2012-11-20 2018-12-20 Phadia Ab Método de pronóstico para individuos con cáncer de próstata

Also Published As

Publication number Publication date
PE20180930A1 (es) 2018-06-08
MX2017013881A (es) 2018-03-12
DE202016008673U1 (de) 2019-01-22
BR112017022391A2 (pt) 2018-07-10
HK1247559A1 (zh) 2018-09-28
EP3287786A2 (en) 2018-02-28
IL254833B (en) 2021-12-01
EP3247387A4 (en) 2018-09-12
US20160320394A1 (en) 2016-11-03
CN107530412A (zh) 2018-01-02
CO2017010808A2 (es) 2018-04-19
MY197117A (en) 2023-05-26
JP6873916B2 (ja) 2021-05-19
TW201705028A (zh) 2017-02-01
EP3247387A1 (en) 2017-11-29
KR102527446B1 (ko) 2023-05-02
US20220399121A1 (en) 2022-12-15
EA201792372A1 (ru) 2018-03-30
CA2982262A1 (en) 2016-11-03
SG11201708289TA (en) 2017-11-29
KR20180018514A (ko) 2018-02-21
EP3287786A3 (en) 2018-03-21
JP2018518661A (ja) 2018-07-12
HK1247824A1 (zh) 2018-10-05
TWI766836B (zh) 2022-06-11
EA039028B1 (ru) 2021-11-24
IL254833A0 (en) 2017-12-31
AU2016254127A1 (en) 2017-10-26
UA125745C2 (uk) 2022-06-01
WO2016176529A1 (en) 2016-11-03
AU2016254127B2 (en) 2022-05-26

Similar Documents

Publication Publication Date Title
PH12020551397A1 (en) Cot modulators and methods of use thereof
CL2017002701A1 (es) Composiciones y métodos para la vigilancia activa del cáncer de próstata.
MX2022009148A (es) Composiciones y metodos para el tratamiento de hemoglobinopatias.
SV2018005684A (es) Anticuerpos que se unen especificamente a pd-1 y sus usos
MY184870A (en) Immunomodulators
MX370807B (es) Anticuerpos que se unen a axl.
PH12016501763A1 (en) Multispecific antibodies
CL2017001185S1 (es) Automovil
BR112018003269A2 (pt) conjugados de fármaco-anticorpo anti-dll3 e métodos de utilização
EA201791029A1 (ru) Антитела против интерлейкина-33 и их применение
PH12018500950B1 (en) Subcutaneous formulations of anti-cd38 antibodies and their uses
MX2016002137A (es) Ciertas entidades quimicas, composiciones y metodos.
MX2016008771A (es) Determinantes de respuesta del cancer a la inmunoterapia.
MX2021010460A (es) Metodo de tratamiento con tradipitant.
EA201792612A1 (ru) 6-аминохинолин-3-карбонитрилы в качестве модуляторов cot
AU363883S (en) Tracking device
MX383748B (es) Procesos para la preparación de un compuesto de diariltiohidantoína.
GB2569488A (en) PD-1 specific aptamers
MY187959A (en) Reactor
CL2017002653A1 (es) Procedimiento y reactor para fijar arsénico.
EA201691203A1 (ru) Твёрдые формы тенофовира
CL2016002256A1 (es) Un proceso mejorado para la preparación de exametazima
ITUA20161552A1 (it) Riflettore modulante per fondo pozzo
UA114708U (uk) Тяговий привід електробуса
UY37009A (es) Formulaciones granuladas de giberelina